drugset / Trial / NCT01353248
GS 5885 Administered Concomitantly With GS-9451, Tegobuvir and Ribavirin (RBV) in Chronic Genotype 1 Hepatitis C Virus (HCV) Infection
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this phase 2 study is to determine whether 30 mg or 90 mg of GS-5885 when given with GS-9451, Tegobuvir and Ribavirin (RBV) for 12 or 24 weeks is effective, safe and tolerable in the treatment of Chronic Genotype 1 HCV Infection.
Timeline
- Start
- 2011-05
- Primary completion
- 2012-10
- Completion
- 2013-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Ledipasvir | Small molecule | 30 mg | — |
| Comparator | Ledipasvir | Small molecule | 90 mg | — |
| Comparator | Ribavirin | Small molecule | 1000 mg | — |
| Comparator | Ribavirin | Small molecule | 1200 mg | — |
| Comparator | Tegobuvir | Small molecule | 30 mg | — |
| Comparator | vedroprevir | Small molecule | 200 mg | — |